Background and study aim: The outcome of patients with hepatocellular carcinoma (HCC) remains poor because of late diagnosis. We aimed to evaluate the performances of serum alpha -1-acid glycoprotein (AAG) for the diagnosis of HCC, especially for HCC with low alphafetoprotein (AFP).
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common malignancies in the world [1]. Alfa-fetoprotein (AFP) has been the most widely used plasma marker for diagnosis, surveillance and as a prognostic indicator of HCC patients' survival [2].
Several studies indicated that high plasma levels of AFP are related to poor prognosis, as well as histologic grade of malignancy [3] . Those with high plasma AFP level at the time of HCC diagnosis have more unfavourable outcomes compared to patients with low AFP level [4] , however, AFP has a low sensitivity in detection of HCC even it often increase in the absence of HCC [5] .
Alpha-1-acid glycoprotein (AAG) is an acute phase protein, synthesized predominantly in the liver. Cytokines can cause plasma AAG level to increase as a part of an inflammatory response [6] . The concentration of AAG significantly increased under the pathologic state of infection, inflammation and tumor and its level may change in various liver diseases as in patients with acute hepatitis and patients with liver cancer [7] . The plasma level of AAG has been suggested to be a potential marker for diagnosing cirrhosis and HCC [8] . It was shown that combination of AAG and AFP improves the accuracy of HCC diagnosis [9] .
In this study we aimed to evaluate the role of AAG in the diagnosis of hepatocellular carcinoma (HCC), and its clinical significance in HCC patients with low AFP (≤20 ng/ml) and in HCC patients with high AFP (>20 ng/ml).
PATIENTS AND METHODS

Patients:
This observational study was conducted on ninety patients admitted to Hepatology and Gastroenterology Department, Beni-seuf general Hospital during the period from March 2016 to September 2016 and a written informed consent was obtained from all participants prior to recruitment and divided into three groups: -Group A: included 30 HCC patients with low AFP (≤20ng/ml). -Group B: included 30 HCC patients with high AFP >20ng/ml). -Group C: included 30 patients with HCV cirrhotics without HCC served as control group.
Liver cirrhosis was documented by clinical evaluation, laboratory investigation and evidence of cirrhosis by abdominal U/S. The diagnosis of HCC was confirmed by triphasic CT according to American association of study of liver diseases [10] . The diagnosis of HCV was dependent on detection of HCV-Ab and confirmed by HCV RNA positivity
Patients bellow 18 years and more 70 years, extremely ill patients, patients with malignancies other than HCC, patients with hepatic metastatic lesions and patients with a previous history of HCC treatment were excluded from the study
Methodology :
The enrolled patients were subjected to full history taking, thorough clinical examination and laboratory investigation including complete blood count (CBC), liver and kidney profile tests Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV)) markers and AFP. Severity of liver cirrhosis assessed by using Modified Child-Pugh score.
Blood sampling and biochemical assays:
Fasting venous blood samples (5ml) were collected by well-trained laboratory technicians under complete aseptic conditions then distributed as follows: a-1 mL of whole blood was collected in an EDTA vacutainer and mixed gently for complete blood count measurement that was performed by automated hematology system (Sysmex XE 5000; Sysmex America, Inc., Mundelein, IL, USA).
b-4 mL of venous blood samples were collected in plain test tubes containing no anticoagulant, allowed to clot for 30 mins at room temperature, then centrifuged for 15 mins at 1000× g. The serum was removed, aliquoted then stored at ≤−20°C until assayed and thawed immediately before the measurement, the separated serum was used for the following assays : -Biochemical tests using Beckman CX4 chemistry analyzer (NY, USA, supplied by the Eastern Co. For Eng, Egypt), these tests including :
• Fasting blood glucose level.
• Liver function tests: Serum albumin, total and direct bilirubin, Liver enzymes including aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase (GGT).
• Kidney function tests : including serum creatinine.
-Viral infection status ( HCVAb and HBS Ag) were assayed using an enzyme immunoassay (EIA) Kit (Abbott, Axyam USA ).
-Serum AFP level (ng/ml)was assyed using an enzyme immunoassay (EIA) Kit (Roche Mannheim, Germany) .
-Serum AAG levels were measured using human ELISA (sandwich technique) kits provided by Human AGP1/alpha 1 acid glycoprotein PicoKine™ ELISA Kit (Boster Biological Technology, Pleasanton CA, USA, Catalog # EK1486) for research use only with assay range 1.56-100 μg/ml.
Assay procedure of AAG :
100 of Standard or diluted sample was added to the bottom of micro ELISA plate well, covered with a new plate sealer, then incubated for 90 minutes at 37 degree, then 100 μL of biotinylated anti human AGP1 antibody was added, covered with a new adhesive strip and incubated at 37 degree for another 60minutes. Aspiration and wash was performed three times followed by addition of 200 μLof Avidin biotin Peroxidase complex (ABC) and incubated at room temperature for another 30 minutes, wash plate 5 times again.90 μL of substrate was added to each well and incubated in the dark for 15-20 minutes. Finally, 100 μL of Stop Solution was added to each well, where the color turned to yellow immediately and the optical density (OD) was read at 450 nm within 30 minutes.
Calculation of results:
The duplicate readings for standard and samples was averaged and subtracted the average zero standard optical density. A standard curve was created by plotting the mean OD value on the Yaxis against the concentration on the X-axis and a fit curve was drawn by some professional software and a best fitting equation of standard curve was calculated using OD values and concentrations of standard samples.
Statistical Analysis:
The statistical analysis was conducted using STATA/SE version 11.2 for Windows (STATA corporation, College Station, Texas). Data are reported as means ± SD, Non-normally distributed data were analyzed by the chi-square test. Spearman pearman correlation test was used to analyse the relation between categorical data. The ROC curve used to determine the most sensitive and specific cut-off value for AAG for diagnosing HCC. Corresponding distribution tables were consulted to get the "P" (probability value). Statistical significance was accepted at P value <0.05.
RESULTS
This study was conducted on 90 cases. The epidemiologic characteristics of the three patients' groups were summarized in Surveillance for HCC usualy depends on AFP and abdominal ultrasonography. yet, the low sensitivity and specificity of AFP make it as a poor biomarker with abdominal ultrasonography for early detection of HCC [11] . so, a good new biomarker is required for early detection of HCC. Plasma level of AAG has been suggested as a new biomarker for HCC and cirrhosis [7] . The aim of this study was to asses the role of AAG in the diagnosis of HCC, especialy with low alfa-fetoprotein (AFP) (≤20 ng/ml) and in HCC with high alfa-fetoprotein (AFP) (>20 ng/ml). In the current study HCC patients were older than cirrhotic HCV patients, (as the mean age in the HCC group A was 59.83 ± 6.16, group B was 62.17±5.41 while in chronic liver disease group C was 45.57±6.20). This finding was in agreement with Shaker who reported that the peak age group for HCC was from 50-70 years with a mean age of 58.7 years [12] . Also in agreement with El-Zayadi et al. who found that patients of the age group 40-59 years were at 3.7 times, and of age group 60 years were at 11 times more risk to develop HCC [13] . Also, there was a male predominance among the HCC groups, (as the number of males were 22 male to 8 female in group A and the number of males were 25 male to 5 female in group B). This finding was in agreement with Sharaf-Eldin et al. Also, El-Serag and Rudolph [16] reported that males have higher liver cancer rates than females, with male: female ratios usually averaging between 2:1 and 4:1 the reasons for higher rates of liver cancer in males may relate to gender specific differences in exposure to risk factors.
The higher incidence of HCC in males might be due to the stimulatory effects of androgen and the protective effect of estrogen. The biological activity of natural progesterone on HCC is controversial and lacks clear investigations [17] . Men are more likely to be infected with HBV and HCV, consume alcohol, smoke cigarettes and have increased iron stores. Higher levels of androgenic hormones, body mass index, and increased genetic susceptibility may also adversely affect male risk [16] . In the present study, HCC cases were more from rural areas, this result was in agreement with Shaker et al. who stated that the incidence of HCC is more common in rural areas than urban [12] . In the present study, AST, AST and serum bilirubin were higher in HCC patients. These results were in agreement with Abu El Makarem et al. who reported that AST and serum bilirubin are higher in HCC patients than cirrhotics [18] . In this study, most of the patients with HCC were Child A and B, followed by Child C, These results were in agreement with Alves et al. who reported that (53.1%) of HCC cases were Child B followed by Child A (31.3%) then Child C (12.5%) [21] . And El-Sawy who reported that (40%) 0f advanced HCC cases were Child B, followed by Child A (32.7%) then Child C (27.3%) [22] .
In the current study there was significant positive correlation between AAG and severity of liver disease (Child-Pugh grade), tumor number and AFP but there was no significant correlation between AAG and the size of the tumor, this goes in agreement with a study by Kanget In this study, ROC analysis of AAG used as a diagnostic test suggested that a cut-off value of 740 μg/ml provides sensitivity, specificity, PPV and NPV for group A of (73.3%, 74.0%, 95.5%, 82.3%) respectively, and for group B(68%, 71%, 91%, 88%) respectively. This shows increase in sensitivity and specificity of AAG in low AFP HCC (group A) more than that in high AFP HCC (group B), so these results allows us to purpose that determining AAG concentration could be especially powerful in patients with HCC especially with non-diagnostic AFP concentrations.
The results of our study are supported by Bachtiar et al. who reported that the level of AAG was low in patients with AFP high HCC but was higher in patients with AFP low HCC. the clinical performance of AAG increased in low AFP HCC( <20 ng/ml) as Sensitivity, accuracy, PPV and NPV of AAG in patients with AFP-low HCC were (82%, 90%, 91%, and 89%, respectively) while in patients with AFP-high HCC Sensitivity, accuracy, PPV, and NPV of AAG were (62%, 82%, 89%, and 79%, respectively). At cut-off value of 800 μg/ml for AAG and 20 ng/ml for AFP [9] .
CONCLUSION
Serum Alpha 1 Acid Glycoprotein (AAG) concentration could be used as a potential marker for hepatocellular carcinoma.
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